Henon 1992.

Methods	Country: France Recruitment: Multicentre Randomisation: Central Blinding ‐ subjects: NS ‐ assessors: NS ‐ therapists: NS Intention‐to‐treat analysis: No Follow‐up: 100% (12 months)
Participants	Inclusion criteria Adults with TTP 28 French natives, 9 natives of other Mediterranean countries. Five patients with cancer (3 treated with mitomycin C and diagnosed with TTP) 5 cases developed due to incorrect treatment with ticlopidine (3), aspirin (2) for venous thrombosis and 3 cases with cimetidine. Pregnancy (2), oral contraceptives (8), tobacco (12), alcoholism (2). Only 37% patients presented with triad of haemorrhage, neurological symptoms, renal impairment. All patients however presented all eligibility criteria at some point in their clinical course. Males/age: 14, median 35 years (range: 19‐62) Females/age: 25, median 39 years (range: 18‐57) Treatment group Number: 19 Control group Number: 19
Interventions	Treatment group Daily PE with FFP (15 mL/kg) in albumin (45 mL/kg) until complete remission achieved. Control group Daily transfusion of FFP (15 mL/kg) until complete remission achieved Both groups received aspirin (10 mL/kg/d) plus dipyridamole (10 mg/kg/d). If treatment or control failed, a common regime of PE with FFP (60 mL/kg/d) tried. After a second failure, salvage therapy (splenectomy, steroids, vincristine, infusion of PGI2), alone or in various combinations, could be tried
Outcomes	Failure of remission at 2 weeks Failure of remission at 1 month All‐cause mortality Relapse rate Complete remission (normalisation of clinical biochemical parameters)
Notes	TTP study Post randomisation exclusions 2 patients, 1 from treatment (due to death prior to treatment) and 1 from control group(due to wrong diagnosis)
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear